Researchers have identified an antioxidant in locally grown black tea leaves as a potential inhibitor of protease activity in SARS-CoV-2, the virus that causes COVID-19, Chiayi Chang Gung Memorial Hospital said on Wednesday.
A research team led by Wu Ching-yuan (吳清源), head of the hospital’s Department of Traditional Chinese Medicine, used a computer program to identify potential antiviral components in traditional plants, the hospital said in a statement.
Theaflavin, a polyphenolic compound, shows broad-spectrum antiviral activity against several viruses and could be used as a lead compound for the development of a SARS-CoV-2 inhibitor to target the DNA-directed ribonucleic acid (RNA) polymerase (RdRp) enzyme.
Photo copied by Lin I-chang, Taipei Times
In coronaviruses, RdRp catalyzes the replication of RNA from a template, making it an attractive candidate to help develop a treatment, Wu said.
RdRp in SARS-CoV-2 is also a primary target for the antiviral remdesivir, which the WHO has called the most promising drug available for the treatment of COVID-19, he said.
Remdesivir works by inhibiting RdRp, which many RNA viruses — including coronaviruses — use to replicate themselves.
The antiviral effects of theaflavin are similar to those of remdesivir, Wu said.
However, the exact in vivo effect is still unclear, and further research is needed to confirm the mechanism whereby theaflavin targets SARS-CoV-2, Wu said.
The findings were published by the American Society for Microbiology in the Journal of Medical Virology on March 13, the hospital said.
In other news, the Central Epidemic Command Center (CECC) on Thursday said that quinoline antimalarial drugs, which have been discussed as a possible treatment for COVID-19, are produced in Taiwan and could be made available if testing proves them to be effective against the novel coronavirus.
In a small French study, doctors used a drug in the quinoline family — hydroxychloroquine — to reduce the duration and severity of COVID-19 symptoms in people with mild cases, said Chang Shan-chwen (張上淳), convener of the center’s expert advisory panel.
If properly tested and approved, a process that normally takes 12 to 18 months, the drug could conceivably reduce the burden on medical resources such as quarantine facilities, Chang said.
Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the CECC, said that there is one manufacturer of quinoline drugs in Taiwan.
If the treatment were proved to be viable, the government’s first priority would be to guarantee domestic supply, Chen said.
The government could participate in the distribution of the drug on the precondition of not harming the manufacturer’s commercial interests, Chen said.
Internationally, drug distribution rights could be used diplomatically to build ties with international partners to address shortages amid the pandemic, he said.
Drugs that have been touted as potentially effective against COVID-19 have become the subject of heated competition in the past few weeks as governments scramble to combat the disease.
Remdesivir is being used on a trial basis in Taiwan and has reduced fevers in the three COVID-19 patients who have been treated with it, although its effect on overall recovery time is still being studied, Chang said.
ANOTHER EMERGES: The CWA yesterday said this year’s fourth storm of the typhoon season had formed in the South China Sea, but was not expected to affect Taiwan Tropical Storm Gaemi has intensified slightly as it heads toward Taiwan, where it is expected to affect the country in the coming days, the Central Weather Administration (CWA) said yesterday. As of 8am yesterday, the 120km-radius storm was 800km southeast of Oluanpi (鵝鑾鼻), Taiwan’s southernmost tip, moving at 9kph northwest, the agency said. A sea warning for Gaemi could be issued tonight at the earliest, it said, adding that the storm is projected to be closest to Taiwan on Wednesday or Thursday. Gaemi’s potential effect on Taiwan remains unclear, as that would depend on its direction, radius and intensity, forecasters said. Former Weather Forecast
As COVID-19 cases in Japan have been increasing for 10 consecutive weeks, people should get vaccinated before visiting the nation, the Centers for Disease Control (CDC) said. The centers reported 773 hospitalizations and 124 deaths related to COVID-19 in Taiwan last week. CDC Epidemic Intelligence Center Director Guo Hung-wei (郭宏偉) on Tuesday said the number of weekly COVID-19 cases reported in Japan has been increasing since mid-May and surpassed 55,000 cases from July 8 to July 14. The average number of COVID-19 patients at Japan’s healthcare facilities that week was also 1.39 times that of the week before and KP.3 is the dominant
The Chinese Communist Party’s (CCP) working group for Taiwan-related policies is likely to be upgraded to a committee-level body, a report commissioned by the Mainland Affairs Council (MAC) said. As Chinese President Xi Jinping (習近平) is increasingly likely to upgrade the CCP’s Central Leading Group for Taiwan Affairs, Taiwanese authorities should prepare by researching Xi and the CCP, the report said. At the third plenary session of the 20th Central Committee of the CCP, which ended on Thursday last week, the party set a target of 2029 for the completion of some tasks, meaning that Xi is likely preparing to
US-CHINA TRADE DISPUTE: Despite Beijing’s offer of preferential treatment, the lure of China has dimmed as Taiwanese and international investors move out Japan and the US have become the favored destinations for Taiwanese graduates as China’s attraction has waned over the years, the Ministry of Labor said. According to the ministry’s latest income and employment advisory published this month, 3,215 Taiwanese university graduates from the class of 2020 went to Japan, surpassing for the first time the 2,881 graduates who went to China. A total of 2,300 graduates from the class of 2021 went to the US, compared with the 2,262 who went to China, the document showed. The trend continued for the class of 2023, of whom 1,460 went to Japan, 1,334 went to